Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2019-07-17 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Initial Details Relating to the Shareholders Register
Regulatory Filings Classification · 1% confidence The document is very short (1746 characters) and explicitly states, "Attached hereto is the Shareholders Register as of the date of this report *C302_isa.pdf*". This structure indicates an announcement about the publication of a specific report (the Shareholders Register) rather than the full report itself. The content relates to the Shareholders Register, which is a specific type of regulatory filing or update concerning ownership structure. Given the options, this is best classified as a general Regulatory Filing (RNS) because 'Shareholders Register' is not a dedicated category, and the document is clearly an announcement of an attachment/publication, fitting the 'MENU VS MEAL' rule for RPA or RNS. Since RNS is the general regulatory fallback and this is a specific regulatory update announcement, RNS is the most appropriate fit over RPA (which is usually for general report publication announcements).
2019-07-17 English
Initial Details of the Corporation’s Securities and the Corporation’s Capital
Share Issue/Capital Change Classification · 1% confidence The document explicitly details the 'Initial Details of the Corporation’s Securities and the Corporation’s Capital,' listing the 'Registered capital,' 'Issued capital,' currency (NIS), and the stock exchange where securities are listed (NASDAQ CM). This content directly relates to the company's capital structure and share details, which aligns with the definition of a Capital/Financing Update (CAP). Although it discusses shares, it is a static report of the current structure rather than an announcement of a transaction (POS) or a new issue (SHA). Given the focus on the existing capital structure details, CAP is the most appropriate classification.
2019-07-17 English
Initial Details of Accountant
Audit Report / Information Classification · 1% confidence The document is a formal filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It is titled 'Initial Details of Accountant' and provides specific information regarding the corporation's appointed accountant, including their name, start date, and address. This type of disclosure, which relates to the company's auditing and financial oversight structure, fits best under the 'Audit Report / Information' category, as it deals directly with the appointed auditor, even though it is not the full audit report itself. Given the specific nature of reporting auditor details to a regulator, AR is the most appropriate fit among the provided options, as it covers applied accounting principles and related reports. It is not a general earnings release (ER), a full annual report (10-K), or a management discussion (MDA). Q2 2019
2019-07-17 English
Registration Document
Regulatory Filings Classification · 1% confidence The document is a detailed filing in Hebrew concerning the registration of ordinary shares and non-tradeable warrants for trading on the Tel Aviv Stock Exchange (TASE). It explicitly mentions the company's registration for trading under Chapter 3e of the Securities Law, requiring its reports to be in English and follow foreign filing formats. The content details the number of shares being registered (10,113,707 ordinary shares plus shares from warrant exercise), the company's structure, contact information, and a detailed description of shareholder rights (dividends, transfer, voting, board structure). The inclusion of appendices referencing US SEC forms like F-20, 10-K, SC 13D, and 3-F, alongside the primary focus on registering securities for a local exchange (TASE) based on foreign listings (NASDAQ), strongly suggests this is a registration statement or a document related to the initial listing/registration process for a foreign private issuer on the TASE. This type of comprehensive document detailing the security being offered/registered and the rights associated with it aligns best with a registration statement, which is often filed under the 'Capital/Financing Update' (CAP) category if it's a primary offering/listing, or sometimes falls under a general 'Regulatory Filing' (RNS) if it's purely for listing compliance without a concurrent public offering. Given the extensive detail about the securities being registered for listing and the reference to US registration forms (like 3-F, which is a registration statement for foreign private issuers), this is fundamentally a document related to capital structure and registration. Since it is not a standard periodic report (10-K, IR) or a simple announcement (RPA), and it deals directly with the issuance and registration of new securities and capital structure details, 'Capital/Financing Update' (CAP) is the most appropriate specific classification, although 'RNS' is a possibility if it were purely a notification. However, the depth suggests a formal registration document related to capital changes/listing.
2019-07-16 English
Registration Document
Audit Report / Information Classification · 1% confidence The document is a 'Registration Document' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It details the listing of ordinary shares on NASDAQ CM and provides contact information and dates. Crucially, the document states: "Attached hereto is a file containing the Registration Document ����_�����_isa.pdf." This indicates the document itself is an announcement or cover sheet regarding the availability of the main Registration Document, rather than the full report or a standard periodic filing like 10-K or IR. Since it announces the publication of a regulatory document and doesn't fit neatly into specific categories like AGM, ER, or DVA, it falls best under the general regulatory announcement category, 'Regulatory Filings' (RNS), or potentially 'Report Publication Announcement' (RPA) if the primary purpose is announcing the publication. Given the context of a 'Registration Document' which is a specific regulatory filing type, RNS is the most appropriate general regulatory fallback, although RPA is also plausible if we strictly follow the 'announcement' rule. However, Registration Documents are often filed as general regulatory disclosures. Given the short length (3130 chars) and the explicit mention of an attached PDF, RPA is a strong candidate, but RNS covers general regulatory disclosures not otherwise specified. Since 'Registration Document' is a formal regulatory filing, RNS is chosen as the best fit for a non-standard, formal regulatory disclosure announcement. FY 2019
2019-07-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.